Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope(®)): data from the PATRO Adults study

BACKGROUND: To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope(®)) in adults with GH deficiency, using data from the ongoing PATRO Adults post-marketing surveillance study. METHODS: PATRO Adults is being conducted in hospitals and special...

Descripción completa

Detalles Bibliográficos
Autores principales: Beck-Peccoz, Paolo, Höybye, Charlotte, Murray, Robert D, Simsek, Suat, Zabransky, Markus, Zouater, Hichem, Stalla, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491215/
https://www.ncbi.nlm.nih.gov/pubmed/32973992
http://dx.doi.org/10.1177/2042018820943377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7491215/
https://www.ncbi.nlm.nih.gov/pubmed/32973992
http://dx.doi.org/10.1177/2042018820943377

Ejemplares similares